drugset / Trial / NCT03834662
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
TGFβ has profound local immunosuppressive and immunoexclusion effects in the tumor microenvironment that are integrally involved in the failure of immune checkpoint inhibitors in some tumors. Preclinical data in a variety of models strongly support the study of AVID200 in patients with treatment-refractory advanced and metastatic malignancies as an approach to reducing immunosuppression/exclusion and increasing the activity of immune checkpoint inhibitors.
Timeline
- Start
- 2019-01-07
- Primary completion
- 2020-02-19
- Completion
- 2020-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVID200 | Protein / enzyme biologic | 180 mg/m2 | Intravenous |
| Subject | AVID200 | Protein / enzyme biologic | 550 mg/m2 | Intravenous |
| Subject | AVID200 | Protein / enzyme biologic | 1100 mg/m2 | Intravenous |